학술논문
Secondary prevention and follow-up of patients with ACS and not-at-target LDL: An Italian real-world retro-prospective analysis by the INERTIA group
Document Type
article
Author
Maurizio Del Pinto; Francesco Amico; Natale Brunetti; Pasquale Caldarola; Stefano Carugo; Claudio Cavallini; Antonello D'Andrea; Francesco Fedele; Ciro Mauro; Patrizia Noussan; Leonardo Paloscia; Francesco Prati; Pierpaolo Tarzia; Maurizio Tespili; Lucia Barbieri; Pierangelo Basso; Andrea Buono; Alberto D'Alleva; Simona Giubilato; Mario Iannacone; Fabio Ferrante; Giuseppina Granata; Riccardo Ieva; Alfredo Madrid; Maria Teresa Mallus; Ercole Tagliamonte
Source
International Journal of Cardiology. Cardiovascular Risk and Prevention, Vol 17, Iss , Pp 200181- (2023)
Subject
Language
English
ISSN
2772-4875
Abstract
Background: In patients with recent ACS, the latest ESC/EAS guidelines for management of dyslipidaemia recommend intensification of LDL-C-lowering therapy. Objective: Report a real-world picture of lipid-lowering therapy prescribed and cholesterol targets achieved in post-ACS patients before and after a specific educational program. Methods: Retrospective data collection prior to the educational course and prospective data collection after the course of consecutive very high-risk patients with ACS admitted in 2020 in 13 Italian cardiology departments, and with a non-target LDL-C level at discharge. Results: Data from 336 patients were included, 229 in the retrospective phase and 107 in the post-course prospective phase. At discharge, statins were prescribed in 98.1% of patients, alone in 62.3% of patients (65% of which at high doses) and in combination with ezetimibe in 35.8% of cases (52% at high doses). A significant reduction was obtained in total and LDL cholesterol (LDL-C) from discharge to the first control visit. Thirty-five percent of patients achieved a target LDL-C